Yeztugo use rises but insurance gaps linger, reinforcing Gilead's adoption challenge

What happened

Reuters reports that use of Gilead's twice-yearly HIV prevention shot Yeztugo has increased since its June launch, but provider feedback indicates patient interest varies and insurance coverage gaps persist. This aligns with DeepValue's assessment that Yeztugo's 2026 ramp to ~$800M depends critically on expanding payer access and re-dosing persistence—key metrics still not publicly disclosed. The CVS Caremark exclusion remains a major bottleneck, limiting covered lives and raising the probability of a slower adoption curve than management's target. While core HIV demand remains strong, the policy-driven price compression from Medicare Part D redesign continues to offset volume growth, capping earnings upside. Gilead's fundamental cash generation supports dividends and buybacks, but the near-term investment case hinges on proving that access improves measurably by mid-2026.

Implication

Yeztugo is gaining traction, but without broader formulary inclusion, the 2026 sales target remains at risk; look for evidence of new PBM contracts and re-dosing data.

Thesis delta

The news validates the bearish risk that adoption is limited by insurance gaps, not just clinical inertia, making the bull case of rapid adoption less probable without new access milestones.